Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/clinem/dgac704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes and Complications of Basal, Bolus, and Combination Insulin Regimens in Type 2 Diabetes Mellitus: Evidence from Published Case Reports.
Diabetes Metab Syndr Obes
September 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Insulin therapy remains a cornerstone in the management of type 2 diabetes mellitus (T2DM), especially in patients experiencing progressive loss of pancreatic beta-cell function or those with inadequate glycemic control despite oral antidiabetic therapy. This review synthesized clinical outcomes from 44 peer-reviewed case reports published between 2019 and 2024, identified through systematic searches in PubMed and Scopus. The included cases involved 15 males and 29 females, with patient ages ranging from 11 to 91 years (mean 53 ± 20.
View Article and Find Full Text PDFThe impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management.
Clin Kidney J
September 2025
Department of Nephrology. University Clinical Hospital, INCLIVA, Valencia. RICORS Renal Instituto de salud Carlos III, Valencia. Spain.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver, heart, and kidneys, focusing on insulin resistance, chronic inflammation, and progressive fibrosis as key mediators.
View Article and Find Full Text PDFResearch Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy.
Rev Cardiovasc Med
August 2025
Department of Cardiology, Gansu Provincial People's Hospital, 730000 Lanzhou, Gansu, China.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising new class of drugs, whose clinical potential has recently been explored. Various preclinical studies and clinical trials initially demonstrated the efficacy of GLP-1RAs in treating type 2 diabetes mellitus (T2DM). However, long-term clinical practice has revealed that GLP-1RAs also exhibit significant efficacy and preventive effects in cardiovascular diseases.
View Article and Find Full Text PDFSemaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review.
Cureus
August 2025
Faculty of Medicine, University of Costa Rica, San Jose, CRI.
This systematic review examines the potential association between semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and the development of non-arteritic anterior ischemic optic neuropathy (NAION). Nine studies were included, consisting of retrospective cohort analyses, case series, and pharmacovigilance reports. Findings across the literature were inconsistent, with some studies reporting an increased risk while others found no significant association.
View Article and Find Full Text PDFEfficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.
EClinicalMedicine
October 2025
Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity. However, it remains inconclusive whether the combination of lifestyle modifications and GLP-1RA interventions can lead to greater weight loss and better control of cardiovascular biomarkers. We aimed to evaluate the efficacy of this combination therapy on weight loss and cardiometabolic markers in adults with overweight or obesity.
View Article and Find Full Text PDF